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T he prevalence of nonhereditary bilateral renal cell carcinoma (RCC) is 4-5% in the world [1 , 2].  
The proportion of patients with bilateral RCC who have 
synchronous tumors ranges from 47% to 71% [3 , 4].  
Bilateral RCC does not belong to any clinical stage.  The 
prognosis of synchronous bilateral RCC is comparable 
to that of unilateral RCC [3 , 4].  Among dialysis 
patients,  the prognosis and quality of life are poor,  
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When a patient is being treated for bilateral RCC,  
the curability and the preservation of the patient’s renal 
function should be taken into account.  Partial nephrec-
tomy (PN) has become the standard of care for stage T1 
RCC,  because of its decreased risk of resulting in 
chronic kidney disease and favorable cancer control 
[5 , 6].  Thermal ablation has emerged as a valid alterna-
tive to nephron-sparing surgery.  Cryoablation (CA) was 
approved by the Japanese national health insurance 
program in 2011 and has been increasingly used.  We 
report the case of a patient with bilateral RCC treated by 
a combination of CA and PN in order to maximize the 
possibility of cancer control and preservation of renal 
function.
Case Report
A 58-year-old Japanese man was referred to our 
institution for the treatment of incidental bilateral renal 
tumors.  His medical history was significant for diabetes 
mellitus (DM),  hypertension (HTN),  and hyperlipid-
emia (HL).  He was taking nifedipine,  olmesartan,  
rosuvastatin,  doxazosin,  spironolactone,  and voglib-
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We report the case of a 58-year-old Japanese man with bilateral synchronous renal cell carcinoma (RCC).  The 
diameters of the right and left tumors were 56 and 69 mm,  respectively.  Both tumors were endophytic.  
Cryoablation with prophylactic embolization was performed for the left tumor,  and 1 month later,  a right open 
partial nephrectomy was performed.  No recurrence was observed during a 16-month follow-up,  and the serum 
creatinine level has been stable.  The prognosis of bilateral synchronous RCC is better than that of dialysis 
patients.  The novel approach of combining cryoablation and partial nephrectomy can achieve good cancer con-
trol and renal function in bilateral RCC.
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ose.  Laboratory test results were normal except for a 
hemoglobin A1c level of 7.2%.  His serum creatinine 
level was 0.83 mg/dL.  Computed tomography (CT) 
revealed bilaterally enhanced renal tumors (Fig. 1).  The 
diameters of the right and left tumors were 56 and 
69 mm,  respectively.  Both tumors were endophytic.  
The respective R.E.N.A.L. nephrometry scores and cen-
trality indices,  which are scoring systems to assess the 
difficulty of nephron-sparing surgery [7] were 11x and 
1.01 for the right kidney and 10p and 0.96 for the left 
kidney.  No metastatic disease was found.
The diagnosis was synchronous bilateral RCC.  The 
treatment options and the order of treatments were 
thoroughly discussed with the patient,  and included 
CA,  PN,  radical nephrectomy,  and renal autotrans-
plantation.  We selected CA for the left tumor to maxi-
mize the possibility of preserving renal function,  taking 
into account the possibility that the tumor in the right 
kidney might require a nephrectomy.
The patient underwent CA of the left kidney twice,  
with a 9-day interval between procedures.  Prophylactic 
tumor embolization was performed to prevent bleeding 
1 day before the first cryotherapy.  Four weeks after the 
second CA,  a right-side open PN was successfully per-
formed without autotransplantation.  The operative 
time was 6 h and 50 min; the cold ischemia time was 
90 min,  and the estimated blood loss was 550 mL.  The 
tumor was resected with attention to meticulous hemo-
stasis.  Good hemostasis was obtained at the time of 
reperfusion,  without the need for parenchymal sutur-
ing.
The pathological examination found clear cell carci-
noma (45 × 40 mm,  pT1b,  G2 > G1,  INF-α,  v0,  ly0).  
The resection margin was negative for cancer.  There has 
been no recurrence at 16 months after surgery.  The 
patient’s serum creatinine level has remained steady at 
1.09 mg/dL,  and the patient does not have proteinuria 
(Fig. 2).
Discussion
We have reported a case of bilateral synchronous 
RCC treated by a novel method that allowed successful 
bilateral renal preservation.  This combination strategy 
has never been reported before,  to our knowledge.  
Bilateral synchronous RCC can be considered to be 
independent primary tumors rather than a single pri-
mary tumor with contralateral renal metastasis.  The 
reported 5-year cancer-specific survival of patients with 
bilateral synchronous RCC was high at 81.5% and 
87.3% in the series from Becker et al.  and Boorjian et 
al.,  respectively,  [3 , 4].  Amano et al.  reported a 4% 
rate of local recurrence for bilateral synchronous RCC 
after PN,  which was significantly lower than the recur-
rence rate of metachronous bilateral RCC (26%,  
p = 0.04) [8].
Of note,  the 5-year survival rate of dialysis patients 
from the start of dialysis in 2009 is 60.5% in Japan.  
Therefore,  the prognosis of dialysis patients is worse 
than the prognosis of patients with bilateral RCC.  
Renal preservation to prevent the need for dialysis and 
to prolong overall survival is a very important treatment 
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Fig. 1　 A, Coronal CT with intravenous contrast medium shows bilateral enhancement of the renal tumors.  The diameter.  of the right 
and left tumors were 56 and 69 mm,  respectively;  B, Coronal CT with intravenous medium 16 months after the partial right nephrectomy 
shows no recurrence of tumor.  Arrow: cryoablation treatment area.  Circle: Partial nephrectomy.
consideration for patients with bilateral renal tumors.  
Our patient was of special concern,  as he had several 
risk factors for chronic renal failure,  including DM,  
HTN and HL.
When we planned the treatment,  the first consider-
ation was to decide which tumor we should treat first.  It 
seemed easier to treat the left tumor compared to the 
right one because of the locations of the tumors.  The 
tumor in the right kidney had a higher score compared 
to the left one,  and it was too close to the renal vessels 
to be treated by any type of ablation therapy,  including 
CA.  There was a high possibility that the patient might 
lose his right kidney.  We therefore treated the left renal 
tumor first to maximize the patient’s renal function and 
avoid dialysis.
The second consideration was to decide which 
modality we should use to achieve good cancer control 
and the preservation of renal function.  CA has recently 
emerged as a valid alternative to nephron-sparing sur-
gery.  The effectiveness of CA for treating T1a renal 
tumors is well established [5 , 6].  In contrast,  its effec-
tiveness for T1b tumors remains undecided.  However,  
the results have been promising.  Atwell et al.  reported 
an estimated 3-year local progression-free survival rate 
of 96.4% for 46 CA procedures for T1b tumors 
[9]; there were 7 (15.2%) major Clavien-Dindo grade II 
or higher complications.  Most of the major complica-
tions were bleeding (4/7).  Prophylactic embolization 
was not performed in these patients [8].
At our institution,  prophylactic embolization is per-
formed to prevent bleeding for tumors > 3 cm,  and our 
major bleeding rate is low at 1.3% (2/174).  Moreover,  
our renal preservation rate after CA is 100%.  In the 
present patient’s case,  we felt that CA for the left tumor 
had a better chance to preserve renal function com-
pared to PN.  However,  since the long-term effective-
ness of CA for T1b RCC is still unclear,  we had to con-
sider that the left renal tumor might lead to a radical 
nephrectomy in the future,  even after CA.  We thus had 
to preserve the patient’s right renal function as much as 
possible.  We prepared for renal autotransplantation at 
the time of surgery for the right renal tumor.  Fortunately,  
the PN was successfully performed.
A combination of CA and PN can be used for bilat-
eral synchronous RCC with preservation of renal func-
tion.  This strategy is a novel method for treating patients 
with renal tumors that have characteristics suggesting 
that bilateral PN will be difficult.
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Fig. 2　 The patientʼs serum creatinine levels and estimated glomerular ﬁltration rate (eGFR) over the course of treatment and follow-up.
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